WO2024214120 - PHARMACEUTICAL COMPOSITIONS OF NILOTINIB
National phase entry is expected:
Publication Number
WO/2024/214120
Publication Date
17.10.2024
International Application No.
PCT/IN2024/050382
International Filing Date
12.04.2024
Title **
[English]
PHARMACEUTICAL COMPOSITIONS OF NILOTINIB
[French]
COMPOSITION PHARMACEUTIQUE DU NILOTINIB
Applicants **
DR. REDDY'S LABORATORIES LIMITED
Inventors
PURAMDAS, Eslavath
KUMAR, Singh Sanjay
MALLIKARJUN, Chaudhari Sangmesh
AVIJIT, Choudhury Anup
Priority Data
202341026974
12.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1951 | |
| EPO | Filing, Examination, Granting | 11561 | |
| Japan | Filing, Examination, Granting | 2026 | |
| South Korea | Filing, Examination, Granting | 1765 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,043
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to immediate release pharmaceutical composition comprising amorphous solid dispersions of the protein kinase inhibitor, nilotinib or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the same. More particularly, the present invention relates to improved pharmaceutical compositions of nilotinib, or a pharmaceutically acceptable salt thereof, that can be administered without regard to food 5 consumption and that can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect. A method of preparation of the said compositions is also dislcosed.[French]
La présente invention concerne une composition pharmaceutique à libération immédiate comprenant des dispersions solides amorphes de l'inhibiteur de protéine kinase, du nilotinib ou un sel pharmaceutiquement acceptable de celui-ci, et des compositions pharmaceutiques les comprenant. Plus particulièrement, la présente invention concerne des compositions pharmaceutiques améliorées de nilotinib, ou d'un sel pharmaceutiquement acceptable de celui-ci, qui peuvent être administrées sans tenir compte de la consommation d'aliments et qui peuvent être administrées à une dose significativement inférieure par rapport à une formulation de nilotinib à libération immédiate disponible dans le commerce, tout en fournissant un effet thérapeutique comparable. L'invention concerne également un procédé de préparation desdites compositions.